Warsaw, Indiana - 7 August 2026: Medartis Inc. today announced the official U.S. launch of the TITAN Nail System, expanding the company’s upper extremity trauma portfolio with a intramedullary fixation solution designed to address fractures of the phalanges and metacarpals.
Medartis launches TITAN Nail System for intramedullary fixation of hand fractures in the US
2 min read Premium comments
fractureMedartisIntramedullary fixationphalangesmetacarpalsTITAN Nail SystemKelly BabineauxRachel EdwardsFDA 501(k) clearance
The first clinical use of the TITAN Nail System was recently performed by Kelly Babineaux, MD at University Medical Center New Orleans on July 29, 2026. The procedure marks the start of the system’s US rollout. as surgeons across the United States begin to gain access to Medartis’ newest fixation platform. The new Titan nail stabilizes the bone from within rather than with a plate-and-screw construct and is designed to reduce soft-tissue exposure and operating time in suitable indications.
“The launch of the TITAN Nail System represents years of collaboration between our engineering clinical, and commercial teams,” said .Rachel Edwards, VP of Marketing, Medartis Inc “We’re excited to bring surgeons a thoughtfully designed intramedullary fixation system that reflects Medartis’ commitment to precision, procedure efficiency, and innovation. Seeing the first successful case performed is an important moment, but it’s only the beginning. We look forward to supporting surgeons as they begin incorporating TITAN into their practices.”
The TITAN Nail System was engineered to provide surgeons with a next-generation intramedullary fixation solution that combines immediate bite force, low and controlled insertion torque, and self-holding instrumentation. Together, these features are intended to simplify nail insertion, enhance procedural efficiency, and provide confident fixation throughout the surgical flow. The implant is delivered in a new procedure kit that is flexible and asset-light for hospitals.
The TITAN Nail received FDA 501(k) clearance in April of 2026 and is now commercially available. Surgeons interested in learning more about the TITAN Nail System or scheduling product training can contact their local Medartis representative or visit www.medartisusa.com.
- ENDS -
Your contact:
Medartis US Corporate Communications
Dave Temple, Executive Director of Marketing Communications, us_corporate_communications@medartis.com
About Medartis
Founded in 1997 and headquartered in Basel, Switzerland, the Medartis Group is one of the world's leading manufacturers and providers of medical devices for surgical fixation of bone fractures and joint replacement for upper and lower extremities as well as for the craniomaxillofacial region. The Group has manufacturing sites in Switzerland, the United States, Brazil, and France. Medartis employs approx. 1,400 individuals across 12 countries, with products offered in over 60 countries globally. Medartis Inc. is the US subsidiary of the Group. For more information, please visit www.medartis.com.
Author
TH
TJ Halvorson
The De Angelis Group | Orthopedics This Week | MSK Innovations
Why This Matters
Two Perspectives
MBA Lens: Economic and industry impact
Medartis Inc. launched the TITAN Nail System in the U.S., expanding its upper extremity trauma portfolio with an intramedullary fixation solution for phalangeal and metacarpal fractures. This strategic move aims to enhance procedural efficiency and reduce operating time by stabilizing bones internally, potentially offering a competitive advantage. The system's asset-light procedure kit also addresses hospital operational needs.
- The launch expands Medartis' market presence in upper extremity trauma, targeting a specific fracture segment with an internal fixation approach.
- The system's design emphasizes procedural efficiency, reduced soft-tissue exposure, and an asset-light kit, potentially impacting hospital costs and adoption.
PhD Lens: Clinical and outcomes impact
The Medartis TITAN Nail System provides intramedullary fixation for phalangeal and metacarpal fractures, stabilizing bone internally rather than with plates. Engineered for precision, it features immediate bite force, low and controlled insertion torque, and self-holding instrumentation. This design aims to simplify nail insertion, enhance procedural efficiency, and ensure confident fixation, reducing soft-tissue exposure compared to external plating.
- The system utilizes intramedullary fixation, stabilizing fractures from within the bone, a distinct mechanism from traditional plate-and-screw constructs.
- Key design features include immediate bite force, controlled insertion torque, and self-holding instrumentation, intended to optimize surgical flow and fixation stability.
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.